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Summary 
Among other effects, prostaglandins (PG) of the E series are known to inhibit several acute and 
chronic inflammatory conditions in vivo and proinflammatory cytokine production by activated 
macrophages in culture. The research presented here demonstrates that the inhibitory effect of 
PGE2 on tumor necrosis factor oe (TNF-oL) and interleukin 6 (IL-6) production by lipopoly- 
saccharide (LPS)-stimulated murine peritoneal macrophages involves IL-10. In a dose-dependent 
manner, PGE2 inhibits LPS-induced release of TNF-ol and IL-6, but not of lactate or nitric oxide. 
The decrease in the level of these cytokines is inversely proportional to the increase in immunoreactive 
IL-10. This differential inhibitory effect of PGE2 is mimicked by agents that elevate intracellular 
levels of cAMP, but not cGMP. Neutralizing anti IL-10 antibody but not neutralizing antibodies 
against other macrophage secretory products (IL-6, leukemia inhibitory factor, and transforming 
growth factor fl [TGF-fl]),  significantly reverse the potent inhibitory effect of PGE2. In vivo, 
the administration of PGE2 before LPS challenge significantly  reduces circulating TNF-cr  and 
IL-6 levels. Anti-IL-10 antibody substantially enhanced the LPS-induced TNF-o~ and IL-6 levels 
in mice that received either LPS alone or LPS plus PGE2. These results suggest that the anti- 
inflammatory effect of PGE2 on mononuclear phagocytes is mediated in part by an autocrine 
feedback mechanism involving IL-10. 
M 
ononuclear phagocytes (macrophages) play a central role 
in the regulation of immune responses as well as in 
both acute and chronic inflammation. The mechanisms that 
participate in these activities are believed to be multifactorial 
and involve macrophage secretory products (for a review see 
reference 1). TNF-ol is an important macrophage inflamma- 
tory cytokine that mediates a wide range of biologic func- 
tions. TNF-c~ is believed to play a major role in septic shock, 
and to contribute to the pathogenesis of AIDS and several 
inflammatory and autoimmune diseases (for reviews see refer- 
ences 2, 3).  Recently, a number of regulatory factors were 
described as having the capacity to block macrophage func- 
tions, including TNF-cr release. These molecules, also termed 
"macrophage-deactivating factors;' include PG of the E se- 
ries (4-8), TGF-3 (9), IL-4 (10), and IL-10 (11, 12). In addi- 
tion to their capacity to induce pain, vascular changes and 
downregulation of T cell functions, PG have been shown to 
exhibit antiinflammatory properties on macrophages. For ex- 
ample, stimulation of macrophages by LPS or by TNF-c~ in- 
duces PGE2 production (13, 14), and the addition of PGE2 
to LPS-stimulated cells inhibits TNF-c~ mRNA expression 
and protein secretion (6-8).  This information leads to the 
hypothesis that the release of PG during LPS-induced inflam- 
mation constitutes a negative-feedback mechanism that limits 
the magnitude of inflammatory cytokine production. In vivo, 
the exogenous administration of PGE suppresses adjuvant ar- 
thritis in rats (15), inhibits the manifestation of interstitial 
nephritis (16), and prolongs the survival of NZB/W F1 fe- 
male autoimmune mice (17). 
IL-10 is a 35-kD protein that can be produced by subpopu- 
lations of T helper cells, B cells, and macrophages. Among 
other properties, IL-10 is a potent inhibitor of monocyte and 
macrophage-derived cytokine synthesis in vitro (for a review 
see reference 18). In vivo, the neutralization of IL-10 by specific 
mAb results in increased levels of TNF-ol and IL-6 (19), and 
the administration of IL-10 effectively protects mice from le- 
thal endotoxemia (20). 
In the current experiments, we establish a connection be- 
tween the macrophage inhibitory effect of PGE2 and IL-10. 
Evidence is presented to support an important role for IL-10 
in the deactivation of murine peritoneal macrophages by 
PGE2. 
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M/c~  Specific  pathogen free, male C57B1/6 and CB6 (BALB/c x 
C57B1/6)F1 mice 9-12 wk old were purchased from Charles River 
Breeding Laboratories  (Wilmington, MA), and they were housed 
under conventional conditions. 
Reagents and Antibodies.  LPS from Salmonella enteriditis, PGE2, 
3-isobutyl-l-methylxanthine (IBMX), dibutyryl (db) cAMP, and 
dbcGMP were purchased from Sigma  Chemical Co.  (St.  Louis, 
MO). The polyclonal rabbit IgG anti-murine leukemia inhibitory 
factor (LIF) and anti-murine  TNFc~,  the rat  IgG1 mAb  anti- 
murine IL-6 (designated  20F3),  the mAb anti-murine Ibl0 (rat 
IgG1, designated 2A5), and isotype control antibody (GLl13) were 
generated and purified as described before (20-22). Neutralizing 
rabbit pan-specific TGF-B IgG was purchased from R&D Systems 
(Minneapolis,  MN). Anti-LIF and anti-TNF-ot were the kind gifts 
of Dr. H. R. Alexander (National Cancer Institute, National In- 
stitutes of Health, Bethesda, MD). 
Macrophage Cultures.  Thioglycollate broth-elicited macrophages 
were prepared as reported previously (23).  Peritoneal lavage was 
performed using 10 ml of cold HBSS containing 10 U/ml heparin. 
Peritoneal exudate ceils were washed and resuspended in culture 
medium (RPMI 1640 containing 10% heat-inactivated FCS, peni- 
cillin,  and streptomycin), and were then plated in 12-well tissue 
culture plates (Coming, Coming, NY) at a cell density of 1.2  x 
106 per weU. After incubation for 90 rain,  the cell monolayers 
were washed three times with complete medium. The cell mono- 
layers were routinely found to contain >95% mononuclear phago- 
cytes. Conditioned medium generated after LPS stimulation for 
24 h was removed, centrifuged, and cell-free supernatants were stored 
at -350C until further analysis. The macrophage monolayers were 
washed three times with PBS, solubilized,  and cellular protein was 
quantified by the bicichoninic acid (Pierce Chemical Co., Rock- 
ford, IL) method. The cells were treated as described in the text 
or figure legends. 
Bioassays and ELISA.  TNF-o~  and IL-6 bioassays were performed 
as previously described (23). The addition of anti-TNF-c~ antibody 
or anti I1--6 (10 #g/ml) resulted in the neutralization of m95% 
of the bioactivity of the corresponding cytokines in the respective 
assays. Murine TNF-ot and 11,10 ELISA kits were obtained from 
Endogen (Boston, MA) and Biosource International (Cammarillo, 
CA), respectively. 
Nitrite concentration as a reflection of nitric oxide release was 
measured using the Griess reagent (24). Lactate concentration was 
measured using reagents from Sigma  Chemical Co. 
Endotoxin-induced Shock.  Mice were injected with PGE2 dis- 
solved in ethanol (200 #g/mouse in 0.2 ml) or with the same amount 
of ethanol dihted in PBS (final ethanol concentration was 9%) 
3 h before the administration of endotoxin (from S. enter/d/t/s)  diluted 
in sterile PBS (0.1 ml/mouse containing 30 #g LPS). 90 min be- 
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Figure  1.  PGE2  suppresses TNF-oe and IL-6, but increases IL-10 release by LPS-stimulated macrophages. Macrophages were pretreated with the in- 
dicated concentration of PGE2, stimulated with LPS (0.5/~g/ml) for 24 h, and cell-free supernatants were subjected to the corresponding assay, as 
described in Materials and Methods. 
2366  Ibl0 Involvement in the Inhibition of TNF-~ Release by PGE2 fore endotoxin challenge, the mice were injected with anti-murine 
IL-10 (2A5, 0.9 mg/mouse in 0.1 ml PBS) or isotype control anti- 
body (GLl13).  All injections were performed via intraperitoneal 
administration. Blood was obtained by a retro-orbital plexus punc- 
ture at 1 and 3 h after LPS challenge, and serum levels of TNF 
and II.,6 were determined  at these time points,  respectively. 
Data Presentation and Statistical Analysis.  Results are expressed 
as mean  _+SD of duplicate determinations  of each duplicate cul- 
ture for every treatment.  Results obtained by ELISA and bioassays 
are shown in picograms per milliliter per 100/xg cell protein, and 
in units  per milliliter per 100 #g cell protein,  respectively. 
Serum TNF-c~ and IL-6 expressed as units  per milliliter were 
determined from five mice in each group. Statistical differences  were 
calculated by analysis of variance (ANOVA). 
Results and Discussion 
Previous reports demonstrated that the addition of PGE2 
to macrophage cultures decreases  LPS-induced stimulation 
of TNF-cr  mRNA and protein levels  (6-8).  To determine 
whether this antiinflammatory effect of PGE2 involves IL-10, 
macrophage monolayers were pretreated with increasing con- 
centrations of PGE2 for 16 h, followed by LPS stimulation 
(500 ng/ml)  for an  additional  24  h.  In  a dose-dependent 
manner,  PGE2  potently inhibits  LPS-induced TNF-c~ and 
IL-6 release, with half-maximal inhibition of "~10 -9 M (Fig. 
1).  In contrast  to the PGE2-induced inhibition  of TNF-ot 
and IL-6 release, the quantification of immunoreactive IL-10 
in the same cell-free supernatants reveals a PGEz-dependent 
augmentation of LPS-induced IL-10 levels. The selective in- 
hibitory action of PGE2 is further reflected by the inability 
of this arachidonic acid metabolite to alter LPS-induced re- 
lease of nitric oxide and of lactate (Fig. 1). These results dem- 
onstrate  that  the addition  of PGE2  to our LPS-stimulated 
cultures is not toxic to the cells. Nearly identical results were 
obtained in three separate experiments, irrespective of whether 
the cells were pretreated with PGE~ or cotreated with PGE2 
plus LPS. In the absence ofLPS macrophages do not produce 
detectable TNF-ot or nitric oxide, but release  10 U/ml per 
100/zg cell protein of IL-6 and 45 mg/dl per  100 #g cell 
protein  of lactate. 
PGE2  is known  to elevate intracellular  cAMP levels via 
stimulation of adenylate cyclase (25). To determine whether 
the  effect  of PGEz  on  IL-10  production  might  relate  to 
changes in intraceUular cAMP, macrophages were treated with 
LPS in the absence or presence of dbcAMP. Fig. 2 demon- 
strates that dbcAMP but not dbcGMP can mimic the differen- 
tial  action  of PGE2  in  reducing  TNF-ot  and  augmenting 
IL-10 production. Also in the figure, the involvement of in- 
tracellular  cAMP is further confirmed by using IBMX, which 
elevates  cAMP levels by inhibiting  phosphodiesterase  and, 
therefore, indirectly blocks the degradation of cAMP (26). 
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Figure 2.  Agents that increase intracellular cAMP inhibit TNF-c~ and 1I.-6,  but increase IL-10  release. Macrophages were pretreated with the indicated 
concentration of dbcAMP, dbcGMP, and IBMX, and were then stimulated with LPS (0.5 #g/ml) for 24 h. 
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ture supernatants of PGE2-treated and LPS-stimulated cells 
is involved in the subsequent reduction in TNF-ol and IL-6 
levels. To this end, neutralizing anti-IL-10,  as well as anti- 
bodies against other macrophage secretory  products, including 
IL-6, LIF, and TGF-~, were added in the presence or absence 
of LPS after pretreatment of macrophages with PGE2. None 
of the above mentioned antibodies stimulates TNF produc- 
tion alone (data not shown). The potent inhibitory effect of 
PGE2 on TNF-ol and IL-6 production is significantly  reversed 
by anti-IL-10,  but not by anti-IL-6, anti-TGF-B, anti-LIF, 
or isotype-control  antibody (Fig. 3). 
IL-10 is known to suppress LPS-induced TNF production 
(18), and anti-IL-10 (2A5) elevates the levels of TNF-ol and 
IL-6 in mice (19). The degree to which anti-IL-10  reverses 
TNF-ot and IL-6 production was, therefore, determined in 
LPS-stimulated cells in the absence and presence of PGE2. 
Fig. 4 shows that whereas TNF-c~ is significantly elevated 
in anti-IL-10 and PGE2-treated cells, the level of the cyto- 
kine is considerably less than that observed in cells treated 
with LPS and anti-IL-lO. Determination of IL-10 by ELISA, 
however, shows that the amount of anti-IL-10 used in these 
experiments is sufficient to totally inactivate the IL-IO released 
by macrophages treated with PGE2 and LPS (Fig. 4). In the 
same experiments,  anti-IL-10  almost  completely  reversed 
PGE2 inhibition of IL-6 levels (no significant difference be- 
tween groups  3 and 5). 
Finally, we attempted to reproduce our in vitro observa- 
tions in endotoxemic mice. A preliminary experiment showed 
that the pretreatment of CB6F1 mice with PGEz (200/~g/ 
mouse intraperitoneally) results in a significant decrease (65% 
reduction, P <0.006)  in circulating TNF-cr  levels 1 h after 
endotoxin challenge (data not shown).  We and others (27) 
have previously shown that the peak of circulating TNF-c~ 
and IL-6 levels can be seen at 1 and 3 h after LPS administra- 
tion, respectively. The experiment shown in Fig. 5 demon- 
strates that PGE2 suppresses TNF-ot and IL-6 levels during 
endotoxin shock by ",70 and 50%, respectively (F <0.002). 
Anti-IL-lO antibody significantly  reversed  the inhibitory effect 
of PGE2 on TNF-a.  However, when compared with the 
augmented serum TNF-c~ levels seen in anti-IL-10-treated 
mice, the reversal of TNF-o~ levels in PGE~. plus anti-IL-10- 
treated animals was incomplete.  In contrast,  serum IL-6 is 
almost completely reversed  by the anti-IL-10 treatment. These 
results are, therefore, in agreement with the data obtained 
in culture.  Namely, anti-IL-10 affords a significant but in- 
complete reversal of the inhibitory effect of PGE2 on TNF-cr 
release, but it appears to completely reverse the PGE2 effect 
on IL-6 production both in vitro and in vivo. Thus, IL-10 
is partially responsible for TNF-ol inhibition but appears to 
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Figure 3.  The inhibitory effect of PGE2 on TNF-ot and IF6 release can be specifically  reversed by anti-IF10 mAb. Cells were pretreated with medium 
or PGE2 (34 nM) and treated with LPS (0.5/~g/ml) plus 20/~g/ml of the indicated antibody. TNF-ot and Ib6 were determined  by ELISA and bioassay, 
respectively. In the absence of LPS, this  concentration  of the antibodies  did not induce  TNF-c~ and II.-6 (not  shown). 
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be  the  major  element responsible  for  IL-6  inhibition by 
PGE2. It is possible that the mechanism of action of PGE2 
involves an additional inhibitory factor(s) that regulates TNF-o~ 
release or that PGE2 directly regulates the synthesis of this 
cytokine. It remains to be established whether induction of 
PG synthesis and the subsequent rise in cAMP that regulates 
IL-10 release is also involved in the negative effect of other 
"macrophage-deactivating factors" such as IL-4 (10) or IL-13 
(28). PG are known to inhibit lymphocyte and macrophage 
functions. For example, PGE2 inhibits chemotaxis and chemo- 
kinesis of lymphocytes (29). Because IL-IO is produced by 
subpopulations of T  helper cells and B cells (18), it is pos- 
sible that the inhibitory effect of PGE2 on lymphocytes also 
involves IL-IO,  as is shown here for murine macrophages. 
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Figure  5.  Anti-Ibl0  partially 
reverses  the  inhibitory  effect  of 
PGE2 on TNF-~ release in endo- 
tc~.emic mice. CB6F1 mice were in- 
jected with PGE2 or PBS, followed 
by the administration of anti-Ibl0 
or isotype control antibody and LPS, 
as described  in Materials and Me- 
thods.  There  were  five  mice per 
group. Serum TNF-cx and Ib6 were 
quantified in L929 and B-9 bioas- 
says, in the absence and presence of 
the corresponding neutralizing mAb. 
2369  Strassmann et al.  Brief Definitive Report In summary, our results provide an explanation to the 
known inhibitory effect of PG on cytokine synthesis by acti- 
vated murine peritoneal macrophages in culture (6-8), and 
they may also explain part of the antiinflammatory effect of 
PGE in vivo (15-17). Collectively, the data strongly suggest 
that bioactive IL-10 is produced by a mechanism involving 
adenylate cyclase during LPS stimulation. In turn, IL-IO con- 
tributes to the control of the magnitude of  macrophage inflam- 
matory profile by a mechanism involving an autocrine pathway. 
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